Renalytix AI plc
("RenalytixAI" or the "Company")

RenalytixAI Expands Core Investigator Group
for Kidney Transplant Advanced Diagnostic Programme

Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces the expansion of the core investigator group supporting clinical and regulatory pathways for FractalDx, a portfolio of advanced diagnostic and prognostic solutions in kidney transplant.

As previously announced, RenalytixAI formed the FractalDx investigator group as part of its commercial programme for advanced diagnostic tests expected to make significant improvements in the identification and monitoring for kidney transplant rejection, and to aid in accurate dosing of immune-suppression therapy.

Kathryn Wood, DPhil, Professor of Immunology Emerita in the Nuffield Department of Surgical Sciences at the University of Oxford, said: “Predicting transplant rejection before damage to the transplanted kidney occurs remains a major unmet need. Accurately determining rejection risk for each transplant recipient allows individualised treatment to be initiated before the transplanted kidney is attacked and damaged by the immune system leading to improved patient care and successful outcomes.”

The number of kidney transplants steadily rises each year in the United States and worldwide with nearly 20 percent of transplants failing within three years. This highlights the critical need for solutions that will address patient impact and the growing cost of medical treatment associated with kidney transplant complications.

Dr. Barbara Murphy, Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai, and Chair of the Scientific Advisory Board of RenalytixAI, said: "As the need for kidney transplantation continues to increase due to the rapid growth of the chronic kidney disease (CKD) epidemic, we must determine a way to assess risk of organ rejection and personalise treatment for each and every patient. Our expanded group of investigators will help us in the ongoing development of prognostic and diagnostic solutions to help address the crucial shortfalls we’re currently facing in the area of kidney transplantation.”

The investigator appointments now include:

- **Richard Formica, MD** – Professor of Medicine (Nephrology) and Professor of Surgery (Transplant); Director of Transplant Medicine; Director Outpatient Transplantation Service; Medical Director Adult and Pediatric Kidney Transplantation; and Medical Director Pancreas Transplantation at Yale School of Medicine

- **Christian P. Larsen, MD, DPhil** – Professor of Surgery, Division of Transplantation, Department of Surgery and the former dean of the Emory University School of Medicine, and Founding Director of the Emory Transplant Center

- **Roslyn B. Mannon, MD** – Professor of Medicine in the Division of Nephrology and Professor of Surgery in the Division of Transplantation at the University of Alabama at Birmingham, and Director of Research for the Comprehensive Transplant Institute

- **Barbara Murphy, MD** – Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai
The FractalDx technology is based principally on sequencing biomarkers from a patient's blood using widely available instrument platforms. Products under development from the portfolio are anticipated to be part of the extended RenalytxAI pipeline following the introduction of KidneyIntelX in 2019 for the diagnosis of fast-progressing chronic kidney disease.

As outlined in an announcement on 2 January, 2019, RenalytxAI had exercised its option from the Icahn School of Medicine at Mount Sinai ("ISMMS") for the exclusive license to technology and data underlying the FractalDx product portfolio. The Company is expected to initiate the clinical validation for the first diagnostic product from the portfolio beginning in the second half of 2019.

Notes:

1 United Network for Organ Sharing (UNOS), 2019
2 National Kidney Foundation, 2019

The person responsible for arranging the release of this announcement on behalf of the Company is James McCullough, CEO.

For further information, please contact:

Renalytx AI plc
James McCullough, CEO
Julian Baines, Non-Executive Chairman

Stifel (Nominated Adviser & Joint Broker)
Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)
Peter Lees (Corporate Broking)

N+1 Singer (Joint Broker)
Tel: 020 7496 3000
Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen / Mia Gardner (Corporate Broking)

Walbrook PR Limited
Paul McManus / Lianne Cawthorne
Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.